Loading
A phase 3 trial of Cadonilimab, Lenvatinib in hepatocellular carcinoma, run by Akeso, now recruiting.
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06371157 by Akeso, with 469 participants planned, started 2024-08-02 and due to reach its primary completion in 2025-10-25. Interventions recorded: AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Hepatocellular carcinoma.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Bispecific antibodies, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.